Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069885 | 0.77 | HDAC3 (0.43) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL30385312 | 0.74 | HDAC3 (0.41) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL4854749 | 0.74 | HDAC3 (0.41) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL560847 | 0.74 | HDAC3 (0.38) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL1564351 | 0.74 | HDAC3 (0.41) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL29612167 | 0.74 | HDAC3 (0.41) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL143063 | 0.74 | HDAC3 (0.38) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL13932579 | 0.74 | HDAC3 (0.38) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL11353696 | 0.74 | HDAC3 (0.38) | HDAC3HSD17B3PARP1CA1CA2 | |
| SCHEMBL6017106 | 0.74 | HDAC3 (0.38) | HDAC3HSD17B3PARP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143668-A | Iron complex based on biisoquinoline and preparation method and application thereof | 万华化学集团股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| CN-106366069-B | A kind of preparation method of N- heteroaryl carbazole compound | 浙江工业大学 | 2019-01-08 | — | — | CN | claimed |
| CN-106366069-A | Preparation method of N-heteroaryl carbazole compounds | 浙江工业大学 | 2017-02-01 | — | — | CN | claimed |
| CN-119176844-A | Platinum-containing complex and application thereof in organic electronic device | 广州追光科技有限公司 | 2024-12-24 | — | — | CN | disclosed |
| CN-119143668-A | Iron complex based on biisoquinoline and preparation method and application thereof | 万华化学集团股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-118930586-A | Near infrared light excited iridium (III) complex photosensitizer, preparation method and application | 华东交通大学 | 2024-11-12 | — | — | CN | disclosed |
| CN-112250667-B | Organic compound, application thereof and organic electroluminescent device using same | 固安鼎材科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-110818739-B | Metal iridium complex with synergistic response to tumor microenvironment pH/hypoxic and application thereof | 南京大学 | 2021-05-28 | — | — | CN | disclosed |
| CN-112250667-A | Organic compound, application thereof and organic electroluminescent device adopting organic compound | 固安鼎材科技有限公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-110818739-A | Metal iridium complex with synergistic response to tumor microenvironment pH/hypoxic and application thereof | 南京大学 | 2020-02-21 | — | — | CN | disclosed |
| EP-1807440-B1 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIV KANSAS (US) | 2020-02-19 | — | — | EP | disclosed |
| US-7622451-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2009-11-24 | — | — | US | disclosed |
| US-7608594-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090187014-A1 | Novobiocin Analogues | UNIVERSITY OF KANSAS | 2009-07-23 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-22 | — | — | US | disclosed |
| EP-1807440-A2 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | The University of Kansas (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1414457-B1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060199776-A1 | Novobiocin analogues as anticancer agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-07 | — | — | US | disclosed |
| WO-2006050501-A2 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIVERSITY OF KANSAS (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | HDAC3 925/4885HSD17B3 2308/4885PARP1 1492/4885 |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | SSB, IAPP, NLN | HDAC3 3836/4885HSD17B3 2831/4885PARP1 264/4885 |
| US-20060199776-A1 | Novobiocin analogues as anticancer agents | HSP90B1, HSP90AB2P, HSP90AB1 | HDAC3 954/4885HSD17B3 3583/4885PARP1 1217/4885 |
| US-20090187014-A1 | Novobiocin Analogues | SSB, SSBP1, BTD | HDAC3 3671/4885HSD17B3 2600/4885PARP1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.